Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches.

Area of Science:

• Oncology
• Thoracic Surgery
• Immunotherapy

Background:

• Lung cancer remains a leading cause of cancer mortality globally.
• Resectable non-small cell lung cancer (NSCLC) treatment typically involves surgery and adjuvant chemotherapy, yet recurrence and death rates remain high.
• Historically, neoadjuvant chemotherapy showed no survival benefit and raised concerns about tumor progression, leading to its decline in favor of adjuvant therapy.

Purpose of the Study:

• To review the emerging evidence for neoadjuvant immunotherapy in resectable NSCLC.
• To discuss the potential of neoadjuvant immunotherapy to improve survival rates in this patient population.
• To explore challenges and perspectives for integrating neoadjuvant immunotherapy into standard NSCLC care.

Main Methods:

• Systematic review of 32 randomized trials (10,000 patients) on preoperative vs. postoperative chemotherapy.
• Review of current clinical trial data on neoadjuvant immunotherapy efficacy.
• Discussion of challenges in defining treatment success and regulatory approval pathways.

Main Results:

• Previous systematic reviews found no survival difference between neoadjuvant and adjuvant chemotherapy.
• Emerging data from ongoing trials suggest significant efficacy for neoadjuvant immunotherapy in resectable NSCLC.
• Potential for neoadjuvant immunotherapy to improve survival outcomes is under investigation.

Conclusions:

• Neoadjuvant immunotherapy is being re-evaluated and shows promise for resectable NSCLC.
• Further research and overcoming regulatory hurdles are necessary to establish it as a standard of care.
• Defining treatment success uniformly is a key challenge for neoadjuvant immunotherapy adoption.